179 related articles for article (PubMed ID: 35477411)
21. Epigenomic profiling of DNA methylation for hepatocellular carcinoma diagnosis and prognosis prediction.
Zhang C; Ge S; Wang J; Jing X; Li H; Mei S; Zhang J; Liang K; Xu H; Zhang X; Zhang C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1869-1877. PubMed ID: 31038805
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2.
Yao Q; Cao Z; Tu C; Zhao Y; Liu H; Zhang S
Cancer Lett; 2013 Jul; 335(1):219-24. PubMed ID: 23435376
[TBL] [Abstract][Full Text] [Related]
23. Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes.
Matsushita J; Suzuki T; Okamura K; Ichihara G; Nohara K
Environ Health Prev Med; 2020 Jul; 25(1):31. PubMed ID: 32703154
[TBL] [Abstract][Full Text] [Related]
24. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
25. STEAP4 promoter methylation correlates with tumorigenesis of hepatocellular carcinoma.
Tang Y; Wang Y; Xu X; Sun H; Tang W
Pathol Res Pract; 2022 May; 233():153870. PubMed ID: 35390632
[TBL] [Abstract][Full Text] [Related]
26. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma.
Qiu W; Zhou B; Zou H; Liu X; Chu PG; Lopez R; Shih J; Chung C; Yen Y
Am J Pathol; 2004 Nov; 165(5):1689-99. PubMed ID: 15509538
[TBL] [Abstract][Full Text] [Related]
27. Study of promoter hypomethylation profiles of RAS oncogenes in hepatocellular carcinoma derived from hepatitis C virus genotype 3a in Pakistani population.
Maryam M; Idrees M
J Med Virol; 2018 Sep; 90(9):1516-1523. PubMed ID: 29742286
[TBL] [Abstract][Full Text] [Related]
28. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
29. FOXC1 promotes HCC proliferation and metastasis by Upregulating DNMT3B to induce DNA Hypermethylation of CTH promoter.
Lin Z; Huang W; He Q; Li D; Wang Z; Feng Y; Liu D; Zhang T; Wang Y; Xie M; Ji X; Sun M; Tian D; Xia L
J Exp Clin Cancer Res; 2021 Feb; 40(1):50. PubMed ID: 33522955
[TBL] [Abstract][Full Text] [Related]
30. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
[TBL] [Abstract][Full Text] [Related]
31. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma.
Li S; Peng F; Ning Y; Jiang P; Peng J; Ding X; Zhang J; Jiang T; Xiang S
J Cell Biochem; 2020 Mar; 121(3):2543-2558. PubMed ID: 31696971
[TBL] [Abstract][Full Text] [Related]
32. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
33. Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma.
Lu B; Ma Y; Wu G; Tong X; Guo H; Liang A; Cong W; Liu C; Wang H; Wu M; Zhao J; Guo Y
Clin Cancer Res; 2008 Nov; 14(22):7405-12. PubMed ID: 19010857
[TBL] [Abstract][Full Text] [Related]
34. Upregulated mH2A1 serves as an unfavorable prognostic indicator and promotes the progress of hepatocellular carcinoma (HCC).
Yang G; Yao Y; Wu D; Guo H; Zhou S; Sun D; Guo X; Zheng T; Wang J; Zhang S; Wang Y; Song R; Ke S; Liu Y; Meng F; Liang Y; Lu Z; Liu L
Life Sci; 2020 Dec; 263():118576. PubMed ID: 33058912
[TBL] [Abstract][Full Text] [Related]
35. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1.
Chen Y; Peng C; Chen J; Chen D; Yang B; He B; Hu W; Zhang Y; Liu H; Dai L; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2019 Aug; 18(1):127. PubMed ID: 31438961
[TBL] [Abstract][Full Text] [Related]
36. Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma.
Zhang T; Guan G; Chen T; Jin J; Zhang L; Yao M; Qi X; Zou J; Chen J; Lu F; Chen X
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e352-e358. PubMed ID: 29749051
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of EGFL8 regulates migration, invasion and apoptosis of hepatocellular carcinoma through activating Notch signaling pathway.
Wu F; Zhang FY; Tan GQ; Chen WJ; Huang B; Yan L; Zhang HL; Chen S; Jiao Y; Wang BL
BMC Cancer; 2021 Jun; 21(1):704. PubMed ID: 34130659
[TBL] [Abstract][Full Text] [Related]
38. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
[TBL] [Abstract][Full Text] [Related]
39. Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1.
Wu WR; Sun H; Zhang R; Yu XH; Shi XD; Zhu MS; Zeng H; Yan LX; Xu LB; Liu C
Oncotarget; 2016 Apr; 7(14):18684-93. PubMed ID: 26919246
[TBL] [Abstract][Full Text] [Related]
40. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer.
Chen M; Zhang J; Li N; Qian Z; Zhu M; Li Q; Zheng J; Wang X; Shi G
PLoS One; 2011; 6(10):e25564. PubMed ID: 22039417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
